NONNWEILER, Germany–(BUSINESS WIRE)–NGMedical GmbH, a medical device manufacturer exclusively focused on creating innovative technologies for spinal application, announces the launch of its new ART® Fixation System in Europe. The ART® Fixation System was developed with the goal of providing the surgeon with a fixation system to perform dorsal spinal stabilizations simply, quickly and effectively. ART® … [Read more…]
Adds two close-to-market innovative technologies to Healiva’s® growing portfolio of end-to-end care for chronic wounds LUGANO, Switzerland–(BUSINESS WIRE)–#celltherapy—Healiva®, a patient-centric company delivering life-enhancing precision medicine for patients with chronic and acute wounds, announced today the acquisition of two innovative cell therapy assets from Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology business. The acquisition enables Healiva® … [Read more…]
PARIS–(BUSINESS WIRE)–Regulatory News: Ipsen (Euronext: IPN; ADR: IPSEY) has appointed an investment-services provider to purchase 125,000 Ipsen S.A. shares, or about 0.15% of the share capital, over a maximum period of three months. The shares purchased under this agreement will be allocated mainly to cover its employee free share-allocation plan. This program is made pursuant … [Read more…]
Presented today at EULAR 2022, data from a new post-hoc analysis show a statistically significant difference in clinical outcomes with subcutaneous (SC) infliximab compared to intravenous (IV) infliximab at week 30, using conservative missing imputation methods Data also show that differences in efficacy outcomes between SC and IV infliximab groups reduced at week 54, after … [Read more…]
VANCOUVER, British Columbia–(BUSINESS WIRE)–Alpha Cognition Inc. (TSX-V: ACOG) (OTCQB: ACOGF) (“Alpha Cognition,” or the “Company”), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating neurodegenerative disorders, announces the grant of stock options pursuant to its stock option plan to certain directors of the Company to … [Read more…]
AURORA, Ontario & DALLAS–(BUSINESS WIRE)–Ovensa Inc. (“Ovensa”), a company enabling the development of targeted therapies and delivery systems using proprietary nanoparticle compositions, and Celanese Corporation, a global chemical and specialty materials company, today announced plans to collaborate on the long-acting controlled release of targeted therapeutics that address current performance, toxicity and resistance challenges in the … [Read more…]
NEW YORK–(BUSINESS WIRE)–Mental Health Awareness Month was designed to nationally decrease the stigma surrounding mental health and encourage open conversation to prevent suicides, violence, depression, and other problems associated with mental health. However, many adolescents, young adults – and their parents – are still in crisis. Drug use among adolescents is up and the CDC … [Read more…]
Experienced Drug Developer Brings Over 25 Years of Clinical Development Industry Knowledge Across Oncology, Immunology, and Infectious Disease Appointment Effective June 1st, 2022 WATERTOWN, Mass.–(BUSINESS WIRE)–SQZ Biotechnologies (NYSE: SQZ), focused on unlocking the full potential of cell therapies for multiple therapeutic areas, today announced that it has appointed Marshelle Smith Warren, M.D., as Chief Medical … [Read more…]
LOUISVILLE, Ky.–(BUSINESS WIRE)–Humana Inc. (NYSE: HUM) announced today that Susan M. Diamond, Chief Financial Officer, will make a presentation to investors at the Jefferies Healthcare Conference on Wednesday, June 8, 2022 at 11:30 a.m. Eastern time. A live audio webcast of the presentation will be available via Humana’s Investor Relations page at humana.com. The company … [Read more…]
Findings from Phase II AtezoTRIBE trial published online in The Lancet Oncology SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–Veracyte, Inc. (Nasdaq: VCYT) announced today that new data published online in The Lancet Oncology suggest that the company’s Immunoscore Immune Checkpoint (IC) assay may identify patients with metastatic colorectal cancer (mCRC) who are likely to benefit from the … [Read more…]
